Last Updated: 9/20/2013
US Food and Drug Administration (FDA)-Approved Antiviral Drugs for Hepatitis C Virus (HCV) Treatment
| boceprevir (BOC) | an NS3/4A protease inhibitor (PI); approved in 2011 |
| peginterferon alfa (PEG IFN) | a synthetic version of a substance normally produced in the body to fight infection; approved in 2001 |
| ribavirin (RBV) | a nucleoside analogue, used in combination with at least 1 other drug; approved in 2001 |
| telaprevir (TVR) | an NS3/4A PI; approved in 2011 |
Investigational Antiviral Drugs for HCV Treatment
This list is not necessarily comprehensive and is intended as an aid in following course presentations.
In Phase III Testing:
| ABT-267 | an NS5A inhibitor |
| ABT-333 | an NS5B polymerase inhibitor |
| ABT-450/r | a ritonavir-boosted (/r) PI |
| asunaprevir | formerly BMS-650032; an NS3 PI |
| daclatasvir | formerly BMS-790052; an NS5A inhibitor |
| deleobuvir | formerly BI 207127; an NS5B polymerase inhibitor |
| faldaprevir | formerly BI 201335; an NS3/4A PI |
| ledipasvir | formerly GS-5885; an NS5A inhibitor |
| mericitabine | an NS5B polymerase inhibitor |
| narlaprevir | formerly SCH 900518; an NS3/NS4A inhibitor |
| simeprevir | formerly TMC435; an NS3/4A PI |
| sofosbuvir | formerly GS-7977; an NS5B polymerase inhibitor |
| vaniprevir | formerly MK-7009; an NS3/4A PI |
In Phase II Testing:
| BMS-791325 | an NS5B polymerase inhibitor |
| danoprevir | formerly RG7227; an NS3/4A PI |
| VX-135 | formerly ALS-2200; an NS5B polymerase inhibitor |
Organizations, Conferences, and Legislation
| AASLD | American Association for the Study of Liver Diseases |
| ASM | American Society for Microbiology |
| CROI | Conference on Retroviruses and Opportunistic Infections |
| DSMB | Data and Safety Monitoring Board |
| DHHS | Department of Health and Human Services |
| EASL | European Association for the Study of the Liver |
| IAS–USA | International Antiviral Society–USA |
| ICAAC | Interscience Conference on Antimicrobial Agents and Chemotherapy |
| NIH | National Institutes of Health |
| NIAID | National Institute of Allergy and Infectious Diseases |
| PPACA or ACA | Patient Protection and Affordable Care Act |
| WHO | World Health Organization |
General Medical Terms
| AE | adverse effect |
| AFP | alpha-fetoprotein |
| AKR | aldo-keto reductase |
| ALT | alanine aminotransferase |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| BLD | below the limit of detection |
| BLQ | below the limit of quantification |
| BMI | body mass index |
| cEVR | complete early virologic response |
| CC, CT, TT | IL28B gene polymorphisms |
| COPD | Chronic Obstructive Pulmonary Disease |
| CP or CTP Score | Child-Pugh Score or Child-Turcotte-Pugh Score |
| CSF | cerebrospinal fluid |
| DAA | direct-acting antiviral |
| DCP | des-gamma-carboxy-prothrombin |
| EGD | esophagogastroduodenoscopy |
| EIA | enzyme immunoassay |
| ELISA | enzyme-linked immunosorbent assay |
| EPO | erythropoietin |
| EOT | end of treatment |
| eRVR | extended rapid virologic response |
| ESLD | end-stage liver disease |
| ETR | end-of-treatment response |
| EVR | early virologic response |
| FIB-4 | a test for hepatic fibrosis |
| Forns index | a test for hepatic fibrosis |
| GGT | gamma-glutamyl transferase |
| GT or gt | genotype |
| HA | hyaluronic acid |
| HAI | histological activity index; used to determine stage of liver disease |
| HbcAb | hepatitis B core antibody |
| HbcAg | hepatitis B core antigen |
| HbeAb | hepatitis B “e” antibody |
| HbeAg | hepatitis B “e” antigen |
| HBIG | hepatitis B immune globulin |
| HbsAb | hepatitis B surface antibody |
| HbsAg | hepatitis B surface antigen |
| HCC | hepatocellular carcinoma |
| HE | hepatic encephalopathy |
| HPS | hepatorenal syndrome |
| HVPG | hepatic venous pressure gradient |
| IFN | interferon alfa |
| IgG | immunoglobulin G |
| IL28B | a genotype that can help indicate likelihood of HCV treatment response to interferon |
| INR | International Normalized Ratio |
| IRES | internal ribosome entry segment |
| ISG | interferon-stimulated gene |
| LFT | liver function test |
| MELD | model for end-stage liver disease; a scoring system for assessing the severity of chronic liver disease |
| Metavir | a scoring system used to determine stage of liver disease |
| OLT | orthotopic liver transplantation |
| pEVR | partial early virologic response |
| P-gp | P–glycoprotein |
| PI | protease inhibitor |
| PR or P/R | peginterferon alfa and ribavirin |
| PT | prothrombin time |
| RAV | resistance-associated variant |
| RGT | response-guided therapy |
| RVR | rapid virologic response |
| SBP | spontaneous bacterial peritonitis |
| SVR | sustained virologic response |
| TIMP | tissue inhibitor of metalloproteinase |
| VL | viral load |
Opportunistic Infections (OIs)
| HAV | hepatitis A virus |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HDV | hepatitis D virus |
| HEV | hepatitis E virus |
| HIV | human immunodeficiency virus |